Related Experiment Video
Updated: Aug 17, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis
Marco Zuin1, Gianluca Rigatelli2, Claudio Bilato3
1Department of Cardiology, West Vicenza Hospital, Arzignano, Vicenza, Italy; Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Insights
COVID-19 survivors face a significantly higher risk of developing myocarditis within a year post-infection. This systematic review highlights myocarditis as a rare but crucial post-acute COVID-19 complication.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Limited data exist on the risk of myocarditis in the post-acute phase of COVID-19.
- Acute myocarditis is a recognized, though infrequent, cardiovascular complication of COVID-19.
Approach:
- A systematic review and meta-analysis of studies published up to September 1, 2022, was conducted.
- Data from 20,875,843 patients, including 1,245,167 COVID-19 survivors, were analyzed.
- Mantel-Haenszel random-effects models were used to pool myocarditis risk data, calculating hazard ratios (HR) and 95% confidence intervals (CI).
Key Points:
- COVID-19 survivors had a myocarditis incidence of 0.21 per 1000 patients versus 0.09 per 1000 in controls.
- Recovered COVID-19 patients showed a 5.16-fold increased risk of incident myocarditis within one year (HR 5.16, 95% CI 3.87-6.89).
- Sensitivity analyses confirmed these findings, indicating robust results.
Conclusions:
- Myocarditis is a rare but significant sequela following COVID-19 infection.
- The findings underscore the importance of monitoring for myocarditis in COVID-19 survivors.
Background:
Acute myocarditis has been described as a relatively rare cardiovascular complication of COVID-19 infection. However, data regarding the risk of myocarditis during the post-acute phase of COVID-19 are scant. We assess the risk of incident myocarditis in COVID-19 survivors within 1 year from the index infection by a systematic review and meta-analysis of the available data.
Methods:
Data were obtained by searching Medline and Scopus for all studies published at any time up to September 1, 2022, and reporting the long-term risk of incident myocarditis in COVID-19 survivors. Myocarditis risk data were pooled using the Mantel-Haenszel random-effects models with hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using the Higgins-Thompson I2 statistic.
Results:
Overall, 20,875,843 patients (mean age 56.1 years, 59.1% male) were included in this analysis. Of them, 1,245,167 experienced (and survived) COVID-19 infection. Over a mean follow-up of 9.5 months, myocarditis occurred to 0.21 (95% CI 0.13-0.42) out of 1000 patients survived to COVID-19 infection compared with 0.09 [95% CI 0.07-0.12) out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of incident myocarditis (HR 5.16, 95% CI 3.87-6.89; P < 0.0001; I2 = 7.9%) within 1 year from the index infection. The sensitivity analysis confirmed yielded results.
Conclusions:
Our findings suggest that myocarditis represents a relatively rare but important post-acute COVID-19 sequelae.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Endocarditis I: Introduction

